4-溴双环[2.2.2]辛烷-1-羧酸 | 1989-50-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 4-溴双环[2.2.2]辛烷-1-羧酸
• 英文名称: 4-Brom-bicyclo<2.2.2>octan-1-carbonsaeure
• 英文别名: 4-bromobicyclo[2.2.2]octane-1-carboxylic Acid
• CAS: 1989-50-0
• 化学式: C₉H₁₃BrO₂
• 分子量: 233.105
• InChiKey: YGDOVZNMGWJAGR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-溴双环[2.2.2]辛烷-1-羧酸 在 氯甲酸 、 三乙胺 、 氨 、 吡啶 、 三氟乙酸 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 4.0h， 以86%的产率得到4-Bromo-bicyclo[2.2.2]octane-1-carbonitrile
  参考文献：
  名称：

  WO2006/128184

  摘要：

  公开号：
• 作为产物：
  描述：

  4-溴双环[2.2.2]辛烷-1-甲酸甲酯 在 sodium hydroxide 、 盐酸 作用下， 以 水 为溶剂， 反应 18.0h， 以82%的产率得到4-溴双环[2.2.2]辛烷-1-羧酸
  参考文献：
  名称：

  WO2006/128184

  摘要：

  公开号：

文献信息

• [EN] SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH<br/>[FR] DIAMINOCARBOXAMIDEPYRIMIDINES ET DIAMINOCARBONITRILEPYRIMIDINES SUBSTITUÉES, COMPOSITIONS DE CELLES-CI ET PROCÉDÉS DE TRAITEMENT À L'AIDE DE CELLES-CI
  申请人：SIGNAL PHARM LLC

  公开号：WO2012145569A1

  公开（公告）日：2012-10-26

  Provided herein are Diaminopyrimidine Compounds having the following structures: wherein R1, R2, R3, and R4 are as defined herein, compositions comprising an effective amount of a Diaminopyrimidine Compound, and methods for treating or preventing liver fibrotic disorders or a condition treatable or preventable by inhibition of a JNK pathway.

  本文提供具有以下结构的二氨基嘧啶化合物：其中R1、R2、R3和R4如本文所定义，包含有效量二氨基嘧啶化合物的组合物，以及用于治疗或预防肝纤维化疾病或通过抑制JNK途径可治疗或预防的疾病的方法。
• Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
  申请人：SIGNAL PHARMACEUTICALS, LLC

  公开号：US10040770B2

  公开（公告）日：2018-08-07

  Provided herein are Diaminopyrimidine Compounds having the following structures: wherein R1, R2, R3, and R4 are as defined herein, compositions comprising an effective amount of a Diaminopyrimidine Compound, and methods for treating or preventing liver fibrotic disorders or a condition treatable or preventable by inhibition of a JNK pathway.

  本文提供了具有以下结构的二氨基嘧啶化合物： 其中R1、R2、R3和R4如本文所定义，包含有效量二氨基嘧啶化合物的组合物，以及治疗或预防肝纤维化疾病或可通过抑制JNK通路治疗或预防的病症的方法。
• Polar substituent effects on fluorine-19 chemical shifts of aryl and vinyl fluorides: a fluorine-19 nuclear magnetic resonance study of some 1,1-difluoro-2-(4-substituted-bicyclo[2.2.2]oct-1-yl)ethenes
  作者：William Adcock、Gaik B. Kok

  DOI：10.1021/jo00207a033

  日期：1985.4
• Binmore, Gavin T.; Walton, John C.; Adcock, William, Magnetic Resonance in Chemistry, 1995, vol. 33, # S1, p. S53 - S59
  作者：Binmore, Gavin T.、Walton, John C.、Adcock, William、Clark, Christopher I.、Krstic, Alexander R.

  DOI：——

  日期：——
• Morphological priming: Dissociation of phonological, semantic, and morphological factors
  作者：Ram Frost、Avital Deutsch、Orna Gilboa、Michal Tannenbaum、William Marslen-Wilson

  DOI：10.3758/bf03211828

  日期：2000.12

  Previous experiments based on a masked-priming paradigm revealed robust morphological priming effects induced by two derivational morphemes in Hebrew: the root and the verbal pattern. However, considering the special characteristics of the masked-priming paradigm, the possible contributions of phonological and/or semantic factors to these morphological effects could not be firmly assessed. In the present study, the role of these factors in morphological priming was examined, using cross-modal presentation. Experiment 1 revealed that priming between morphologically related words in Hebrew is determined by higher level linguistic characteristics and cannot be reduced to phonological overlap. Experiment 2 confirmed that morphological priming occurs in Hebrew even when primes and targets are not semantically related but, nevertheless, increases with semantic similarity. The results support the claim that morphological priming cannot be accounted for by considering semantic and phonological factors alone, and they exemplify the potential of using both masked and cross-modal priming to examine morphological processing.